Compare AU
Compare CURE vs. MHOT
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the VanEck Morningstar Wide Moat (Aud Hedged) ETF (MHOT). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
CURE | MHOT | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 79 | 2 |
Median incremental investment | $624.65 | $2,553.00 |
Median investment frequency | Monthly | Fortnightly |
Median total investment | $1,353.14 | $6,004.84 |
Average age group | > 35 | > 35 |
Key Summary
CURE | MHOT | |
|---|---|---|
Strategy | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. | MHOT.AX was created on 2023-11-07 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. MHOT.AX gives investors exposure to a diversified portfolio of attractively priced US companies with sustainable competitive advantages according to Morningstars equity research team. MHOT.AX aims to provide investment returns before fees and other costs which track the performance of the Index with returns hedged into Australian dollars. |
Top 3 holdings | AbbVie Inc (2.62 %) Alnylam Pharmaceuticals Inc (2.59 %) Amgen Inc (2.59 %) | Gilead Sciences Inc (3.41 %) Bristol-Myers Squibb Co (2.95 %) The Walt Disney Co (2.79 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | Other (81.41 %) Health Care (6.60 %) Consumer Staples (3.91 %) |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | United States (98.74 %) Netherlands (1.26 %) |
Management fee | 0.45 % | 0.52 % |
Key Summary
CURE | MHOT | |
|---|---|---|
Issuer | Global X | VanEck |
Tracking index | S&P Biotechnology Select Industry | Morningstar Wide Moat Focus Index - AUD - Benchmark TR Net Hedged |
Asset class | ETF | ETF |
Management fee | 0.45 % | 0.52 % |
Price | $46.66 | $130.54 |
Size | $33.491 million | $60.794 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 4.24 % | 0.11 % |
Market | ASX | ASX |
First listed date | 12/11/2018 | 08/11/2023 |
Purchase fee | $6.50 | $6.50 |
Community Stats
CURE | MHOT | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 79 | 2 |
Median incremental investment | $624.65 | $2,553.00 |
Median investment frequency | Monthly | Fortnightly |
Median total investment | $1,353.14 | $6,004.84 |
Average age group | > 35 | > 35 |
Pros and Cons
CURE | MHOT | |
|---|---|---|
Pros |
|
|
Cons |
|
|
CURE | MHOT |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |